Clinical Trial Update: The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation [Phase 2]

View source ↗

Summary

Resverlogix reports completion of a Phase 2 trial evaluating RVX-208, an apolipoprotein A-I stimulator, in patients with coronary artery disease and dyslipidemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Dyslipidemia

Drugs mentioned

• RVX-208 (apolipoprotein A-I synthesis stimulator)

Snippet

Sponsor: Resverlogix Corp | Conditions: Coronary Artery Disease, Dyslipidemia | Phase 2 | Status: COMPLETED